US 11400164
Immunoconjugates targeting HER2
granted A61KA61K39/395A61K47/6801
Quick answer
US patent 11400164 (Immunoconjugates targeting HER2) held by Bolt Biotherapeutics, Inc. expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Bolt Biotherapeutics, Inc.
- Grant date
- Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 44
- CPC classes
- A61K, A61K39/395, A61K47/6801, A61K47/6803, A61K47/6835